OAT-4828
/ Molecure
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
September 26, 2025
Therapeutic inhibition of USP7 promotes antitumor immune responses.
(PubMed, J Immunother Cancer)
- "Overall, OAT-4828 demonstrates significant anticancer efficacy in melanoma and colon cancer models by activating the immune system, suggesting that USP7 may function as a checkpoint contributing to immunosuppression in cancer."
Journal • Colon Cancer • Colorectal Cancer • Melanoma • Oncology • Solid Tumor • Targeted Protein Degradation • PD-L1 • USP7
June 29, 2025
The development of a USP7 inhibitor for cancer immunotherapy
(EACR 2025)
- "Material and The activity and selectivity of OAT- 4828, an inhibitor we designed, was assessed in enzymatic assays... We conclude that USP7-MDM2-p53 is implicated in the antitumor function of immune cells and shapes the tumor microenvironment. Altogether, we confirm USP7 as an attractive target for cancer immunotherapy and present a strong rationale for the development of USP7 inhibitors for clinical use."
Chronic Lymphocytic Leukemia • Colon Cancer • Colorectal Cancer • Hematological Malignancies • Immunology • Leukemia • Lymphoma • Melanoma • Oncology • Solid Tumor • Targeted Protein Degradation • CD69 • GZMB • IFNG • IL2RA • MDM2 • USP7
1 to 2
Of
2
Go to page
1